Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255424 · ClinicalTrials.gov registry record · Phase 3
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients
A Phase 3 study, sponsored by AMAG Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 304
- Enrollment target
NCT00255424 is a Phase 3 study that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 304 participants.
The verdict
NCT00255424, a Phase 3 study, has completed, sponsored by AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 304 participants
- Enrollment target
Study Summary
The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients with chronic kidney disease who are not on dialysis.
Interventions
- DRUG ferumoxytol or oral iron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2004-05 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00255424
The ClinicalTrials.gov registry entry for NCT00255424 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AMAG Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ferumoxytol or oral iron is the first listed.
NCT00255424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00255424 about?
NCT00255424 is a clinical study titled "Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients". The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients with chronic kidney disease who are not on dialysis.
What is the current status of trial NCT00255424?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 304 participants. The study started on 2004-05. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00255424?
The interventions under investigation include: ferumoxytol or oral iron (DRUG).
Who is sponsoring clinical trial NCT00255424?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.